Clinical Trial Update: A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating allogeneic CAR gamma-delta T cells in patients with relapsed or refractory solid tumors; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Allogeneic CAR Gamma-Delta T Cells (CAR gamma-delta T cells)

Snippet

Sponsor: Ever Supreme Bio Technology Co., Ltd. | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING